1-1 of 1
Keywords: Checkpoint inhibition
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Comparison of First-Line Anti-PD-1-Based Combination Therapies in Metastatic Renal-Cell Carcinoma: Real-World Experiences from a Retrospective, Multi-Institutional Cohort

Available to Purchase
Subject Area:
Further Areas
Benedikt Hoeh, Philipp Schmucker, Niklas Klümper, Oliver Hahn, Philip Zeuschner, Severine Banek, Pierre I. Karakiewicz, Jörg Ellinger, Julia Heinzelbecker, Michael Hölzel, Arne Strauß, Friedemann Zengerling, Angelika Mattigk, Charis Kalogirou
Journal: Urologia Internationalis
Urol Int (2022) 106 (11): 1150–1157.
https://doi.org/10.1159/000521661
Published Online: 14 February 2022
... for differences in overall (OS) and progression-free survival (PFS) rates and toxicity in first-line immune checkpoint inhibition (IO) combination therapy in metastatic renal-cell carcinoma (mRCC) patients. Methods: Between November 2017 and April 2021, 104 patients with histologically confirmed mRCC from 6...
View article titled, Comparison of First-Line Anti-PD-1-Based Combination Therapies in Metastatic Renal-Cell Carcinoma: Real-World Experiences from a Retrospective, Multi-Institutional Cohort
Open the PDF for Comparison of First-Line Anti-PD-1-Based Combination Therapies in Metastatic Renal-Cell Carcinoma: Real-World Experiences from a Retrospective, Multi-Institutional Cohort in another window